{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T22:49:40Z","timestamp":1782168580281,"version":"3.54.5"},"reference-count":74,"publisher":"Elsevier","isbn-type":[{"value":"9780128241271","type":"print"}],"license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/bs.podrm.2020.07.002","type":"book-chapter","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T08:36:08Z","timestamp":1597998968000},"page":"91-136","source":"Crossref","is-referenced-by-count":7,"title":["Betaxolol: A comprehensive profile"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.podrm.2020.07.002_bb0010","unstructured":"Betaxolol. [cited 2020 28 April]; Available from: http:\/\/www.chemspider.com\/Chemical-Structure.2279.html?rid=51ec5bde-d3ec-4052-a90c-d8d663a221e3&page_num=0."},{"key":"10.1016\/bs.podrm.2020.07.002_bb0015","unstructured":"Betaxolol. [cited 2020 28 April]; Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Betaxolol."},{"key":"10.1016\/bs.podrm.2020.07.002_bb0020","unstructured":"Betaxolol Hydrochloride. [cited 2020 28 April]; Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Betaxolol-hydrochloride."},{"key":"10.1016\/bs.podrm.2020.07.002_bb0025","unstructured":"Betaxolol Hydrochloride. [cited 2020 April 28]; Available from: http:\/\/www.chemspider.com\/Chemical-Structure.97073.html?rid=87554247-d426-46f4-b56b-aba14e53fe13."},{"key":"10.1016\/bs.podrm.2020.07.002_bb0030","unstructured":"Levobetaxolol. [cited 2020 28 April]; Available from: http:\/\/www.chemspider.com\/Chemical-Structure.54669.html?rid=462492d8-ef1f-45c5-9947-2ee71d6a08f6."},{"key":"10.1016\/bs.podrm.2020.07.002_bb0035","unstructured":"Levobetaxolol hydrochloride. [cited 2020 28 April]; Available from: http:\/\/www.chemspider.com\/Chemical-Structure.54668.html?rid=f5a1d7b8-8cdf-4da1-8c76-889afa927dea."},{"key":"10.1016\/bs.podrm.2020.07.002_bb0040","unstructured":"Levobetaxolol. [cited 2020 28 April]; Available from: https:\/\/www.drugbank.ca\/drugs\/DB09351."},{"key":"10.1016\/bs.podrm.2020.07.002_bb0045","series-title":"Clarke's Analysis of Drugs and Poisons in Pharmaceuticals, Body Fluids and Postmortem Material","year":"2011"},{"key":"10.1016\/bs.podrm.2020.07.002_bb0050","unstructured":"Betaxolol Brand Names. [cited 2020 28 April]; Available from: https:\/\/www.drugs.com\/ingredient\/betaxolol.html."},{"key":"10.1016\/bs.podrm.2020.07.002_bb0055","unstructured":"Kerledex. [cited 2020 28 April]; Available from: https:\/\/www.rxlist.com\/kerledex-drug.htm."},{"key":"10.1016\/bs.podrm.2020.07.002_bb0060","series-title":"Martindale: The Complete Drug Reference. Drug Monographs","author":"Sweetman","year":"2011"},{"key":"10.1016\/bs.podrm.2020.07.002_bb0065","unstructured":"Percent Composition Calculator. [cited 2020 28 April]; Available from: http:\/\/www.chemhaven.org\/che101\/tools\/percentcomp\/percentcomp.cgi."},{"issue":"1","key":"10.1016\/bs.podrm.2020.07.002_bb0070","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2165\/00003495-198631010-00002","article-title":"Betaxolol: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension","volume":"31","author":"Beresford","year":"1986","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/bs.podrm.2020.07.002_bb0075","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1021\/jm00389a008","article-title":"Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases","volume":"30","author":"Manoury","year":"1987","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/bs.podrm.2020.07.002_bb0080","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/jlcr.2580250902","article-title":"The synthesis of betaxolol labelled with tritium at high specific activity","volume":"25","author":"Allen","year":"1988","journal-title":"J. Label. Compd. Radiopharm."},{"issue":"10","key":"10.1016\/bs.podrm.2020.07.002_bb0085","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1021\/jo0602367","article-title":"Selective terminal Heck arylation of vinyl ethers with aryl chlorides: a combined experimental-computational approach including synthesis of betaxolol","volume":"71","author":"Datta","year":"2006","journal-title":"J. Org. Chem."},{"issue":"8","key":"10.1016\/bs.podrm.2020.07.002_bb0090","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.tet.2006.12.016","article-title":"Concise synthesis of \u03b2-blockers (S)-metoprolol and (S)-betaxolol using hydrolytic kinetic resolution","volume":"63","author":"Muthukrishnan","year":"2007","journal-title":"Tetrahedron"},{"key":"10.1016\/bs.podrm.2020.07.002_bb0095","series-title":"Process for Preparation of S-(-)-betaxolol and Salts Thereof","author":"Joshi","year":"2006"},{"issue":"5","key":"10.1016\/bs.podrm.2020.07.002_bb0100","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1556\/JPC.16.2003.5.3","article-title":"Study of the lipophilicity and retention behavior of some beta-adrenoceptor antagonists","volume":"16","author":"Peri\u0161i\u0107-Janji\u0107","year":"2003","journal-title":"JPC-J. Planar Chromat."},{"issue":"2","key":"10.1016\/bs.podrm.2020.07.002_bb0105","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0223-5234(94)90214-3","article-title":"Chromatographic hydrophobicity parameter determined on an immobilized artificial membrane column: relationships to standard measures of hydrophobicity and bioactivity","volume":"29","author":"Kaliszan","year":"1994","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/bs.podrm.2020.07.002_bb0110","unstructured":"Betaxolol Solubility. [cited 2020 28 April]; Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/2369#section=Solubility."},{"issue":"3","key":"10.1016\/bs.podrm.2020.07.002_bb0115","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1007\/s10973-012-2765-9","article-title":"Polymorphism and melt crystallisation of racemic betaxolol, a \u03b2-adrenergic antagonist drug","volume":"111","author":"Maria","year":"2013","journal-title":"J. Therm. Anal. Calorim."},{"issue":"1\u20133","key":"10.1016\/bs.podrm.2020.07.002_bb0120","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.molstruc.2008.04.029","article-title":"The structure of betaxolol from single crystal X-ray diffraction and natural bond orbital analysis","volume":"891","author":"Canotilho","year":"2008","journal-title":"J. Mol. Struct."},{"issue":"4","key":"10.1016\/bs.podrm.2020.07.002_bb0125","doi-asserted-by":"crossref","first-page":"833","DOI":"10.5012\/bkcs.2008.29.4.833","article-title":"Prediction of melting point for drug-like compounds using principal component-genetic algorithm-artificial neural network","volume":"29","author":"Habibi-Yangjeh","year":"2008","journal-title":"Bull. Korean Chem. Soc."},{"key":"10.1016\/bs.podrm.2020.07.002_bb0130","series-title":"36\/National Formulary 31","author":"United States Pharmacopeia","year":"2013"},{"issue":"2","key":"10.1016\/bs.podrm.2020.07.002_bb0135","article-title":"Spectrophotometric method for simultaneous determination of betaxolol hydrochloride and chlorthalidone in tablet formulation by simultaneous equation method","volume":"2013","author":"Patel","year":"2013","journal-title":"Inventi Rapid: Pharm Analysis & Quality Assurance"},{"issue":"6","key":"10.1016\/bs.podrm.2020.07.002_bb0371","first-page":"31","article-title":"Spectrophotometric determination of betaxolol in pure form and pharmaceuticals","volume":"5","author":"Zhuk","year":"2016","journal-title":"Pharma Innov. J."},{"issue":"2","key":"10.1016\/bs.podrm.2020.07.002_bb0140","article-title":"Spectrophotometric estimation of Betaxolol Hydrochloride in bulk powder and its dosage forms","volume":"68","author":"Suhagia","year":"2006","journal-title":"Indian J. Pharm. Sci."},{"issue":"3","key":"10.1016\/bs.podrm.2020.07.002_bb0145","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0731-7085(02)00100-0","article-title":"Spectrophotometric determination of \u03b2-adrenergic blocking agents in pharmaceutical formulations","volume":"29","author":"Salem","year":"2002","journal-title":"J. Pharm. Biomed. Anal."},{"issue":"3","key":"10.1016\/bs.podrm.2020.07.002_bb0150","doi-asserted-by":"crossref","first-page":"228","DOI":"10.2174\/157341110791517007","article-title":"Kinetic spectrophotometric determination of Betaxolol, Clopidogrel and Imidapril in pharmaceutical preparations","volume":"6","author":"El Yazbi","year":"2010","journal-title":"Curr. Anal. Chem."},{"key":"10.1016\/bs.podrm.2020.07.002_bb0155","doi-asserted-by":"crossref","DOI":"10.21608\/zjps.2005.177794","article-title":"Spectrofluoremetric determination of Betaxolol in dosage forms and spiked","author":"Sultan","year":"2005","journal-title":"Zagazig J. Pharma. Sci."},{"issue":"1","key":"10.1016\/bs.podrm.2020.07.002_bb0160","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1080\/03639040600975154","article-title":"Polymer membrane electrodes for sensitive potentiometric determination of \u03b2-blockers","volume":"33","author":"Wassil","year":"2007","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"2","key":"10.1016\/bs.podrm.2020.07.002_bb0165","first-page":"332","article-title":"Potentiometric sensor for the determination of Betaxolol hydrochloride in plasma and urine","volume":"41","author":"Alturiqi","year":"2016","journal-title":"Int. J. Pharm. Sci. Rev. Res."},{"key":"10.1016\/bs.podrm.2020.07.002_bb0170","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.bioelechem.2013.04.002","article-title":"Multivariate curve resolution-alternating least squares assisted by voltammetry for simultaneous determination of Betaxolol and atenolol using carbon nanotube paste electrode","volume":"94","author":"Khoobi","year":"2013","journal-title":"Bioelectrochemistry"},{"issue":"5","key":"10.1016\/bs.podrm.2020.07.002_bb0175","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.tetasy.2015.01.017","article-title":"Chirality recognition for assessing the enantiomeric purity of Betaxolol","volume":"26","author":"Vashistha","year":"2015","journal-title":"Tetrahedron: Asymmetry"},{"issue":"4","key":"10.1016\/bs.podrm.2020.07.002_bb0180","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1556\/JPC.16.2003.4.6","article-title":"Densitometric and videodensitometric TLC determination of timolol and betaxolol in ophthalmic solutions","volume":"16","author":"Hopka\u0142a","year":"2003","journal-title":"JPC-J. Planar Chromat."},{"issue":"4","key":"10.1016\/bs.podrm.2020.07.002_bb0185","first-page":"643","article-title":"Development and validation of stability-indicating TLC-densitometric method for determination of Betaxolol with LC-ESI\/MS analysis of degradation product","volume":"70","author":"Kwiecie","year":"2013","journal-title":"Acta Pol. Pharm. Drug Res."},{"issue":"10","key":"10.1016\/bs.podrm.2020.07.002_bb0190","first-page":"1630","article-title":"Capillary electrophoresis determination of betaxolol hydrochloride tablets","volume":"27","author":"Zhang","year":"2007","journal-title":"Chin. J. Pharma. Anal."},{"issue":"15\u201317","key":"10.1016\/bs.podrm.2020.07.002_bb0195","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/1615-9314(20021101)25:15\/17<1087::AID-JSSC1087>3.0.CO;2-A","article-title":"Optimization of the separation of \u03b2-blockers by ion-pair capillary electrophoresis in non-aqueous media using univariate and multivariate approaches","volume":"25","author":"Servais","year":"2002","journal-title":"J. Sep. Sci."},{"key":"10.1016\/bs.podrm.2020.07.002_bb0200","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/ACI.S11256","article-title":"A rapid stability-indicating RP-HPLC method for the determination of betaxolol hydrochloride in pharmaceutical tablets","volume":"8","author":"Auvity","year":"2013","journal-title":"Anal. Chem. insights"},{"key":"10.1016\/bs.podrm.2020.07.002_bb0205","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1177\/117739010600100003","article-title":"Direct enantiomeric resolution of betaxolol with application to analysis of pharmaceutical products","volume":"1","author":"Hefnawy","year":"2006","journal-title":"Anal. Chem. insights"},{"key":"10.1016\/bs.podrm.2020.07.002_bb0210","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0378-4347(00)83287-9","article-title":"Determination of betaxolol enantiomers by high-performance liquid chromatography: application to pharmacokinetic studies","volume":"374","author":"Darmon","year":"1986","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"issue":"13","key":"10.1016\/bs.podrm.2020.07.002_bb0215","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1080\/10826076.2011.627600","article-title":"Separation of betaxolol hydrochloride with new bonded cellulose chiral stationary phase and determination of the enantiomers in plasma by HPLC","volume":"35","author":"Zhou","year":"2012","journal-title":"J. Liq. Chromatogr. Relat. Technol."},{"key":"10.1016\/bs.podrm.2020.07.002_bb0220","first-page":"308","article-title":"Investigation on enantiomeric separation of betaxolol hydrochloride by normal phase chiral HPLC and stability","author":"Ke","year":"2010","journal-title":"Zhengzhou Daxue Xuebao, Yixueban"},{"issue":"9","key":"10.1016\/bs.podrm.2020.07.002_bb0225","first-page":"1207","article-title":"HPLC determination of betaxolol hydrochloride in human plasma","volume":"26","author":"Du","year":"2006","journal-title":"Chin. J. Pharma. Anal."},{"issue":"1","key":"10.1016\/bs.podrm.2020.07.002_bb0230","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1570-0232(02)00023-5","article-title":"Determination of betaxolol in human aqueous humour by high-performance liquid chromatography with fluorescence detection","volume":"772","author":"Dulger","year":"2002","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/bs.podrm.2020.07.002_bb0235","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0378-4347(87)80113-5","article-title":"Column liquid chromatographic measurement of betaxolol in plasma or serum","volume":"417","author":"Bhamra","year":"1987","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"key":"10.1016\/bs.podrm.2020.07.002_bb0240","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/S0378-4347(00)84710-6","article-title":"Simple method for routine determination of betaxolol in blood and urine by automated high-performance liquid chromatography with fluorimetric detection","volume":"311","author":"Caqueret","year":"1984","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"issue":"3","key":"10.1016\/bs.podrm.2020.07.002_bb0245","article-title":"Determination of betaxolol in human plasma by high-performance liquid chromatography with fluorescence detection","volume":"4","author":"Wu","year":"2007","journal-title":"Life Sci. J."},{"issue":"1","key":"10.1016\/bs.podrm.2020.07.002_bb0250","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0379-0738(88)90007-2","article-title":"A specific HPLC method for determination of \u03b2-blockers topically used in ophthalmological diseases","volume":"38","author":"Tracqui","year":"1988","journal-title":"Forensic Sci. Int."},{"issue":"3","key":"10.1016\/bs.podrm.2020.07.002_bb0255","first-page":"191","article-title":"Pharmacokinetics and relative bioavailability of betaxolol hydrochloride tablets in Chinese healthy volunteers","volume":"23","author":"Gao","year":"2007","journal-title":"Chin. J. Clin. Pharm."},{"issue":"1","key":"10.1016\/bs.podrm.2020.07.002_bb0260","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.forsciint.2003.12.008","article-title":"Simultaneous determination of thirteen \u03b2-blockers and one metabolite by gradient high-performance liquid chromatography with photodiode-array UV detection","volume":"141","author":"Delamoye","year":"2004","journal-title":"Forensic Sci. Int."},{"issue":"11","key":"10.1016\/bs.podrm.2020.07.002_bb0265","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s11434-012-5636-7","article-title":"Separation of four-lol drugs by HPLC with new bonded chiral stationary column","volume":"58","author":"Zhou","year":"2013","journal-title":"Chin. Sci. Bull."},{"issue":"2","key":"10.1016\/bs.podrm.2020.07.002_bb0270","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1080\/00032719.2013.838677","article-title":"Enantioseparation of orciprenaline, betaxolol, and propranolol using HPLC and new chiral reagents based on 1,5-Difluoro-2, 4-dinitrobenzene","volume":"47","author":"Bhushan","year":"2014","journal-title":"Anal. Lett."},{"key":"10.1016\/bs.podrm.2020.07.002_bb0275","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S0021-9673(01)81470-9","article-title":"Direct enantiomeric separation of betaxolol with applications to analysis of bulk drug and biological samples","volume":"452","author":"Krstulovi\u0107","year":"1988","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/bs.podrm.2020.07.002_bb0280","first-page":"1137","article-title":"Preparation and evaluation of ion sensitive & thermosensitive in situ gel of betaxolol hydrochloride for ophthalmic use","author":"Yuan","year":"2013","journal-title":"Zhongguo Yiyuan Yaoxue Zazhi"},{"key":"10.1016\/bs.podrm.2020.07.002_bb0285","first-page":"553","article-title":"Simultaneous estimation of betaxolol hydrochloride and hydrochlorothiazide from tablets by RP-HPLC","volume":"29","author":"Erram","year":"1992","journal-title":"Indian Drugs-Bombay"},{"issue":"1","key":"10.1016\/bs.podrm.2020.07.002_bb0290","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1167\/iovs.05-0945","article-title":"Concentrations of betaxolol in ocular tissues of patients with glaucoma and normal monkeys after 1 month of topical ocular administration","volume":"47","author":"Holl\u00f3","year":"2006","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"issue":"8","key":"10.1016\/bs.podrm.2020.07.002_bb0295","first-page":"1342","article-title":"Development of extraction procedure for analysis of sedatives and \u03b2-blockers in swine kidney","volume":"37","author":"Oliveira","year":"2014","journal-title":"Qu\u00edm. Nova"},{"issue":"19","key":"10.1016\/bs.podrm.2020.07.002_bb0300","doi-asserted-by":"crossref","first-page":"5719","DOI":"10.1007\/s00216-015-8752-9","article-title":"Renewable sorbent material for solid phase extraction with direct coupling of sequential injection analysis-bead injection to liquid chromatography-electrospray ionization tandem mass spectrometry","volume":"407","author":"Boonjob","year":"2015","journal-title":"Anal. Bioanal. Chem."},{"issue":"3","key":"10.1016\/bs.podrm.2020.07.002_bb0305","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.jchromb.2008.12.027","article-title":"Cassette analysis of eight beta-blockers in bovine eye sclera, choroid\u2013RPE, retina, and vitreous by liquid chromatography\u2013tandem mass spectrometry","volume":"877","author":"Kadam","year":"2009","journal-title":"J. Chromatogr. B"},{"issue":"1","key":"10.1016\/bs.podrm.2020.07.002_bb0310","first-page":"133","article-title":"Analysis by liquid chromatography\u2013electrospray ionization tandem mass spectrometry and acute toxicity evaluation for \u03b2-blockers and lipid-regulating agents in wastewater samples","volume":"1046","author":"Hernando","year":"2004","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/bs.podrm.2020.07.002_bb0315","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0378-4347(00)84359-5","article-title":"Improved determination of betaxolol in biological samples by capillary column gas chromatography","volume":"275","author":"Ganansia","year":"1983","journal-title":"J. Chromatogr. B Biomed. Sci. Appl."},{"issue":"1","key":"10.1016\/bs.podrm.2020.07.002_bb0320","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1089\/jop.1994.10.57","article-title":"Ion exchange resins for ophthalmic delivery","volume":"10","author":"Jani","year":"1994","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/bs.podrm.2020.07.002_bb0325","series-title":"A Rapid Stability-Indicating RP-HPLC Method for the Determination of Betaxolol Hydrochloride in Pharmaceutical Tablets","author":"Auvity","year":"2013"},{"issue":"9\u201310","key":"10.1016\/bs.podrm.2020.07.002_bb0330","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.3109\/03639049609065938","article-title":"Stability-indicating HPLC method for betaxolol HCl and its pharmaceutical dosage forms","volume":"22","author":"Mahalaxmi","year":"1996","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"9","key":"10.1016\/bs.podrm.2020.07.002_bb0335","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1177\/1060028013503137","article-title":"Stability of betaxolol suspensions in oral syringes and glass bottles","volume":"47","author":"Verdier","year":"2013","journal-title":"Ann. Pharmacother."},{"issue":"1","key":"10.1016\/bs.podrm.2020.07.002_bb0340","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2165\/00003495-199040010-00005","article-title":"Ocular betaxolol","volume":"40","author":"Buckley","year":"1990","journal-title":"Drugs"},{"issue":"11","key":"10.1016\/bs.podrm.2020.07.002_bb0345","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/S0161-6420(83)34380-3","article-title":"The mechanism of betaxolol, a new ocular hypotensive agent","volume":"90","author":"Reiss","year":"1983","journal-title":"Ophthalmology"},{"key":"10.1016\/bs.podrm.2020.07.002_bb0350","unstructured":"Betaxolol Prescribing Information. 2007 [cited 2020 28 April]; Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2007\/019845s020lbl.pdf."},{"issue":"8","key":"10.1016\/bs.podrm.2020.07.002_bb0355","doi-asserted-by":"crossref","first-page":"358","DOI":"10.5414\/CPP41358","article-title":"Betaxolol-induced deterioration of asthma and a pharmacodynamic analysis based on beta-receptor occupancy","volume":"41","author":"Miki","year":"2003","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/bs.podrm.2020.07.002_bb0360","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0006-8993(96)01393-5","article-title":"In vivo and in vitro experiments show that betaxolol is a retinal neuroprotective agent","volume":"751","author":"Osborne","year":"1997","journal-title":"Brain Res."},{"issue":"4","key":"10.1016\/bs.podrm.2020.07.002_bb0365","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/jps.2600800407","article-title":"Human pharmacokinetics of betaxolol enantiomers","volume":"80","author":"Stagni","year":"1991","journal-title":"J. Pharm. Sci."},{"issue":"5","key":"10.1016\/bs.podrm.2020.07.002_bb0370","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2165\/00044011-199714050-00004","article-title":"Effects of ocular betaxolol on glucose and lipid metabolism after long-term treatment","volume":"14","author":"Caccavale","year":"1997","journal-title":"Clin. Drug Investig."}],"container-title":["Profiles of Drug Substances, Excipients and Related Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512520300145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871512520300145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:35:16Z","timestamp":1761730516000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871512520300145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"ISBN":["9780128241271"],"references-count":74,"URL":"https:\/\/doi.org\/10.1016\/bs.podrm.2020.07.002","relation":{},"ISSN":["1871-5125"],"issn-type":[{"value":"1871-5125","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]}}}